FDAorphan designation65% confidence
Medical Products for Rare Diseases and Conditions
Source: FDA
Why This Matters
Why this matters: provides agency context on orphan designation that may shape timing or evidence expectations for Roche.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Alzheimer's Disease
- Sub-indication
- General
Related signal: Hoffmann-La Roche initiates trial for trontinemab in early symptomatic Alzheimer's disease